4%) and the high/positive expression was in 739

4%) and the high/positive expression was in 739 patients (55.6%). It seemed that patients bearing low/negative BRCA1 had a higher ORR to platinum-based chemotherapy than those bearing high/positive BRCA1 level (48.9% vs 38.1%, OR = 1.70, 95%CI = 1.32-2.18, I 2 = 44.7%, P = 0.03 for heterogeneity) (Figure 2). No publication bias was observed (P = 0.15). In subgroup analysis based on BRCA1 detection method, there were 13 IHC studies (1066 patients) [16, 17, 19, 21–28, 33] and 4 RT-PCR studies (264 patients) [10, 18, 20, 29], the distribution of low/negative BRCA1 was similarity(IHC vs RT-PCR: 44.5% vs 44.3%). Both of them found

Selleckchem EPZ004777 the significant association (for IHC studies, 50.7% vs 39.0%, OR = 1.54, 95%CI = 1.17-2.00, I 2 = 44.8%, P = 0.03 for heterogeneity; for RT-PCR studies, 43.7% vs 25.0%, OR = 2.91, 95%CI = 1.55-3.83, I 2 = 0.0%, P = 0.52 for heterogeneity), When we stratified studies according to their origin, 13 studies were conducted in CRT0066101 purchase East-Asian [16–25, 27, 28, 33] and only 3 were Caucasian [10, 26, 29]. The low/negative BRCA1 level distribution in Caucasian was lower than East-Asian (38.6% vs 45.4%).The significant association was found in East-Asian population rather than Caucasian: for East-Asian, 51.0% vs 36.0%, OR = 1.68, 95%CI = 1.30-2.19, I 2 = 39.9%, P = 0.04 for heterogeneity; for Caucasian, 39.8% vs 33.4%, OR = 1.77, 95%CI = 0.50-6.28,

I 2 = 63.6%, P = 0.06 for heterogeneity. However, the relationship between BRCA1 level and ORR in Caucasian population could not be determined as the sample size was not large enough. 7 studies consisted of 3 East-Asian [18, 30, 32] and 4 Caucasian [10, 26, 29, 31] including Selleckchem Momelotinib 733 patients were used to analyzed the OS. The significant association between BRCA1 expression and OS in platinum-based treatment was detected. Patients bearing low/negative BRCA1 was more likely to have longer survival time. (HR = 1.58, 95%CI = 1.27-1.97, I 2 = 48.4%, P = 0.03 for heterogeneity) (Figure 3), no publication bias was observed (P = 0.13). EFS data

were available for 5 Amylase studies [26, 29, 31, 32, 36] with 599 patients (3 were PFS [26, 29, 32], one was DFS [31] and the other one was TTP [36]),only one study was about East-Asian[32]. It seemed that patients with low/negative BRCA1 had longer EFS than those with high level, even there was no publication bias, but heterogeneity existed between studies. (HR = 1.60, 95%CI = 1.07-2.39) (I 2 = 54.5%, P = 0.02 for heterogeneity) (Figure 4). 2. Taxol-based chemotherapy Since only 2 studies [35, 36] presented the sufficient data of OS and EFS that ensured us to conducted meta-analysis. We didn’t evaluate the relationship between BRCA1 expression and OS/EFS. In ORR analysis, we applied 4 eligible studies (2 East-Asian and 2 Caucasian) [34–37] in our meta-analysis.

Comments are closed.